Abstract
Nivolumab Combined with Brentuximab Vedotin for Relapsed/Refractory Mediastinal Gray Zone Lymphoma: Primary Efficacy and Safety Analysis of the Phase 2 CheckMate 436 Study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have